Healthcare company Organon (NYSE:OGN) announced on Tuesday that it has acquired the US regulatory and commercial rights to TOFIDENCE, a biosimilar to ACTEMRA, from biotechnology company Biogen Inc (Nasdaq:BIIB).
TOFIDENCE, launched in May 2024, is the first FDA-approved tocilizumab biosimilar in the United States. It is indicated for multiple inflammatory conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.
Under the agreement, Organon gains exclusive US rights to TOFIDENCE in three vial sizes for intravenous infusion, while Bio-Thera Solutions Ltd, the product developer, retains manufacturing rights.
Organon has made an upfront payment to Biogen and will assume Biogen's obligation to pay tiered royalties and annual net sales milestone payments to Bio-Thera Solutions.
This acquisition strengthens Organon's biosimilars portfolio and expands its presence in the US immunology market.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne